DEA Props Up Outdated Cannabis Policy with Rescheduling Scheme

Despite concerns about a pharmaceutical entity grabbing control of the cannabidiol (CBD) market, many legalization activists thrilled at the announcement that Epidiolex received approval by the Food and Drug Administration (FDA) back in June. It was reasonable to hope that the approval of a cannabis-based drug for use in treating serious medical conditions would soon […]